First preclinical evaluation of [225Ac]Ac-DOTA-JR11 and comparison with [177Lu]Lu-DOTA-JR11, alpha versus beta radionuclide therapy of NETs

• Главные авторы: Maryana Handula (Автор), Savanne Beekman (Автор), Mark Konijnenberg (Автор), Debra Stuurman (Автор), Corrina de Ridder (Автор), Frank Bruchertseifer (Автор), Alfred Morgenstern (Автор), Antonia Denkova (Автор), Erik de Blois (Автор), Yann Seimbille (Автор)
• Формат: ‌
• Опубликовано: SpringerOpen, 2023-06-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Abstract Background The [177Lu]Lu-DOTA-TATE mediated peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors (NETs) is sometimes leading to treatment resistance and disease recurrence. An interesting alternative could be the somatostatin antagonist, [177Lu]Lu-DOTA-JR11, that demonstrat...